Efficacy and safety of endoscopic papillectomy: a multicenter, retrospective, cohort study on 227 patients.
ampullary tumor
endoscopic papillectomy
endoscopic resection
post-ERCP pancreatitis
Journal
Therapeutic advances in gastroenterology
ISSN: 1756-283X
Titre abrégé: Therap Adv Gastroenterol
Pays: England
ID NLM: 101478893
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
12
2021
accepted:
11
03
2022
entrez:
28
4
2022
pubmed:
29
4
2022
medline:
29
4
2022
Statut:
epublish
Résumé
Endoscopic papillectomy is a minimally invasive treatment for benign tumors of the ampulla of Vater or early ampullary carcinoma. However, reported recurrence rates are significant and risk factors for recurrence are unclear. The aims of this study were to evaluate the efficacy and safety of endoscopic papillectomy and to identify risk factors for recurrence and adverse events. All patients who underwent endoscopic papillectomy at five tertiary referral centers between January 2008 and December 2018 were included. Recurrence was defined as the detection of residue on one of the follow-up endoscopies. Treatment success was defined as the absence of tumor residue on the last follow-up endoscopy. A total of 227 patients were included. The resections were Endoscopic papillectomy is an effective and relatively well-tolerated treatment for localized ampullary tumors. In this series, R1 resection, intraductal invasion, and lesion size > 2 cm were associated with local recurrence.
Sections du résumé
Background
UNASSIGNED
Endoscopic papillectomy is a minimally invasive treatment for benign tumors of the ampulla of Vater or early ampullary carcinoma. However, reported recurrence rates are significant and risk factors for recurrence are unclear.
Objective
UNASSIGNED
The aims of this study were to evaluate the efficacy and safety of endoscopic papillectomy and to identify risk factors for recurrence and adverse events.
Methods
UNASSIGNED
All patients who underwent endoscopic papillectomy at five tertiary referral centers between January 2008 and December 2018 were included. Recurrence was defined as the detection of residue on one of the follow-up endoscopies. Treatment success was defined as the absence of tumor residue on the last follow-up endoscopy.
Results
UNASSIGNED
A total of 227 patients were included. The resections were
Conclusion
UNASSIGNED
Endoscopic papillectomy is an effective and relatively well-tolerated treatment for localized ampullary tumors. In this series, R1 resection, intraductal invasion, and lesion size > 2 cm were associated with local recurrence.
Identifiants
pubmed: 35480299
doi: 10.1177/17562848221090820
pii: 10.1177_17562848221090820
pmc: PMC9036320
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17562848221090820Informations de copyright
© The Author(s), 2022.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Surgeon. 2017 Oct;15(5):251-258
pubmed: 26711559
United European Gastroenterol J. 2020 Feb;8(1):44-51
pubmed: 32213054
Gastrointest Endosc. 2021 Oct;94(4):760-773.e18
pubmed: 33887269
Am J Surg. 1997 Sep;174(3):355-8
pubmed: 9324155
Surg Innov. 2004 Dec;11(4):255-63
pubmed: 15756395
Gastrointest Endosc. 2007 Oct;66(4):701-7
pubmed: 17905011
Gastrointest Endosc. 2017 Apr;85(4):746-755
pubmed: 27566056
Dig Endosc. 2012 Jan;24(1):30-5
pubmed: 22211409
Endoscopy. 2014 Feb;46(2):127-34
pubmed: 24477368
J Gastrointest Surg. 2000 Jan-Feb;4(1):13-21, discussion 22-3
pubmed: 10631358
Arch Surg. 2009 Nov;144(11):1074-80
pubmed: 19917946
J Clin Med. 2020 Nov 10;9(11):
pubmed: 33182806
Gastrointest Endosc. 1993 Mar-Apr;39(2):127-31
pubmed: 8495831
United European Gastroenterol J. 2019 Apr;7(3):369-376
pubmed: 31019705
Surg Endosc. 2013 Oct;27(10):3865-76
pubmed: 23708714
J Gastroenterol Hepatol. 2009 Jan;24(1):120-4
pubmed: 19032444
Surg Endosc. 2021 Feb;35(2):684-692
pubmed: 32215745
Gastrointest Endosc. 2005 Sep;62(3):367-70
pubmed: 16111953
World J Gastroenterol. 2019 Mar 21;25(11):1387-1397
pubmed: 30918431
Gastrointest Endosc. 2009 Nov;70(5):923-32
pubmed: 19608181
United European Gastroenterol J. 2018 May;6(4):576-585
pubmed: 29881613
Gastrointest Endosc. 2010 Mar;71(3):446-54
pubmed: 20189503
Gastrointest Endosc. 2015 Nov;82(5):773-81
pubmed: 26260385
Gastrointest Endosc Clin N Am. 2003 Oct;13(4):649-69
pubmed: 14986792
J Can Assoc Gastroenterol. 2020 Feb;3(1):17-25
pubmed: 32010876
Gastrointest Endosc. 2021 Oct;94(4):774-775
pubmed: 34419246
N Engl J Med. 2012 Apr 12;366(15):1414-22
pubmed: 22494121
BMC Gastroenterol. 2017 May 30;17(1):69
pubmed: 28558658
Endoscopy. 2021 Apr;53(4):429-448
pubmed: 33728632
Gastrointest Endosc. 1997 Mar;45(3):251-60
pubmed: 9087831
Dig Endosc. 2019 Mar;31(2):188-196
pubmed: 30161275
Gastrointest Endosc. 2018 Sep;88(3):511-518
pubmed: 29660322
Surg Endosc. 2013 Sep;27(9):3377-87
pubmed: 23549765
Gastrointest Endosc. 2014 Feb;79(2):289-96
pubmed: 24094466
Cancer. 1988 Apr 1;61(7):1394-402
pubmed: 3422832